




THE UNIVERSITY OF  
MELBOURNE



Melbourne Bioinformatics  
BIOINFORMATICS + DATA SERVICES + INFRASTRUCTURE, FOR LIFE SCIENCES TODAY



BUCHANAN LAB

# Germline POLE and POLD1 variation in persons with colorectal cancer from the Colon Cancer Family Registry Cohort

Khalid Mahmood  
Melbourne Bioinformatics,  
Colorectal Oncogenomics Group,  
University of Melbourne  
InSiGHT, 2019

# Germline POLE and POLD1 in Colorectal Cancers (CRCs)

- Germline mutations in POLE and POLD1 are associated with CRCs
- Recurring germline exonuclease domain mutations (EDMs):
  - POLE: p.Leu424Val
  - POLD1: p.Leu474Pro and p.Ser478Asn
- EDMs result in defective proofreading function
  - structural proximity to DNA binding/active sites likely perturbs function
  - resulting in characteristic hypermutator phenotype
  - also shown by functional assays in yeast and T4 bacteriophage

## Aims

- Identify new germline mutations in POLE and POLD1 using a large cohort of persons with CRC
- Incorporate clinico-pathological and tumour molecular features to classify new POLE and POLD1 pathogenic variants

# Study cohort: Colon Cancer Family Registry (CCFR)

## Australian cohort

## Ontario cohort

## Seattle cohort

Cases: recruited as population based probands diagnosed with CRC

Incident CRC dx between  
18-59 yrs (independent of  
FHx)

Incident CRC dx between  
20-74 yrs (weighted to  
FHx)

Incident CRC dx between  
18-74 yrs (independent of  
FHx)

Controls: recruited by random sampling from population without prior CRC


Cases = 861  
Controls = 247

Cases = 633  
Controls = 575

Cases = 459  
Controls = 385

**Cases = 1953**  
**Controls = 1207**

# Results: germline POLE predicted pathogenic variants




■ Exonuclease  
■ Polymerase  
■ DUF

● SPLICE  
● MISSENSE  
● NONSENSE  
● FRAMESHIFT


	POLE	POLE_exo
Cases (n=1953)	21 (1.09%)	4 (0.21%)
Controls (n=1207)	10 (0.84%) OR 1.3 [0.61-2.75] P=5.8E-01	0 (0%) OR - p=3.1E-01
gnomAD (n=123134)	1168 (0.96%) OR 1.1 [0.74-1.74] P=5.6E-01	111(0.1%) OR 2.27 [0.84-6.16] p=1.1E-01

# Results: germline POLD1 predicted pathogenic variants



	POLD1	POLD1_exo
Cases (n=1953)	19 (0.98%)	8 (0.41%)
Controls (n=1207)	5 (0.42%) OR 2.35 [0.88-6.27] P=9.3E-02	2 (0.17%) OR 2.47 [0.53-11.62] p=3.4E-01
gnomAD (n=123134)	438 (0.36%) OR 2.73 [1.73-4.32] P=1.4E-04	84 (0.07%) OR 6.0 [2.91-12.38] p=7.6E-05

# Characterising POLE exonuclease domain mutations (EDMs)





■ Exonuclease  
■ Polymerase  
■ DUF

**Use matching tumour molecular features to characterise POLE EDMs**

● SPLICE  
● MISSENSE  
● NONSENSE  
● FRAMESHIFT

POLE:p.Lys280Asn  
 POLE:p.Asp301Gly  
 POLE:p.Lys398Arg


# Results: Somatic mutational signature analysis



[TCT→A] and [TCG→T] mutations are enriched in tumours with POLE EDMs



# Results: Tumour mutation burden analysis



\*Campbell BB. et.al. Cell (2017)


# Summary

<b>POLE EDMs</b>	<b>In silico prediction (CADD, REVEL)</b>	<b>gnomAD</b>	<b>Predicted structure stability (DynaMut)* yeast POL2 structure 4m8o</b>	<b>Mutational Signature.10</b>	<b>Mutation burden (mut/Mb)</b>	<b>ClinVar classification</b>
<b>p.Asp301Gly</b>	31.0, 0.7	8.12E-06 (1 in 100k)	destabilising	High	Ultra-hypermutator	VUS
<b>p.Lys280Asn</b>	27.7, 0.28	ultra-rare	destabilising	Low	Low mutation burden	VUS
<b>p.Lys398Arg</b>	17.8, 0.15	ultra-rare	stabilising	Low	Ultra-hypermutator	VUS

\*DynaMut, Rodrigues CHM et.al. NAR (2018)

## Conclusions and Future directions

- Analysing matching tumour molecular features can help characterise EDMs
- Future directions for EDM characterisation
  - incorporate structural and functional data
  - perform segregation analysis for variant characterisation



# Acknowledgments

## Colorectal Oncogenomics Group, UoM



A/Prof Dan Buchanan  
 Dr Mark Clendenning  
 Dr Bernard Pope  
 Dr Harindra Jayasekara  
 Dr Eric Ji-Hoon Joo  
 A/Prof. Christophe Rosty  
 Dr Abi Ragunathan  
 Sharelle Joseland  
 Susan Preston  
 Thomas Green  
 Peter Georgeson  
 Romy Walker

## Colon Cancer Family Registry Collaborators

**Ontario Institute of Cancer Research**  
 Prof. Steven Gallinger  
 Dr Ashton Connor

**Melbourne Bioinformatics**  
 A/Prof Daniel Park

**Precision Medicine, Monash**  
 Prof Melissa Southey  
 Dr Tu Nguyen-Dumont  
 Members of GEL

**[ACCFR] Centre for Epidemiology &  
 Biostatistics, UoM**  
 Prof Mark Jenkins  
 Prof John Hopper  
 Dr Aung Win

**Royal Melbourne Hospital**  
 Prof Ingrid Winship  
 Prof Finlay Macrae

**University of Virginia, School of  
 Medicine**  
 Prof. Graham Casey


<http://www.buchananlab.org/>



**Translational Genomics Research Institute (TGEN)**  
 Assoc. Prof. David Duggan  
**Mayo Clinic**  
 Prof. Stephen Thibodeau  
 Prof. Laney Lindor

**Australasian Colorectal Cancer Family Registry**  
**Colon Cancer Family Registry Cohort**  
**Genetics of Colonic Polyposis Study**

# Structural analysis



● predicted pathogenic variants

# Somatic POLE and POLD1 mutations (COSMIC)

